Worth reading
66In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
-262
¥ millionWording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
Fiscal year ending February 2027 · Second quarter (interim period) and full yearPrevious forecast published 13 April 2026Net Sales—→—million
—
Operating profit—→—million
—
Ordinary income—→—million
—
Profit attributable to owners of the parent—→—million
—
Net income per share—→—yen and sen
—
The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Reason for the revision
Orders from domestic cosmetics manufacturers fell below expectations amid heightened tensions in the Middle East, some large orders from overseas cosmetics manufacturers were postponed, costs increased due to higher crude oil prices and inflation, particularly for petroleum-derived products, and the passing of higher costs through to order prices was delayed. Sales and earnings at the French consolidated subsidiary are expected to exceed forecasts, supported by the recovery in orders for pharmaceuticals and cosmetics and the weaker yen, but the decline in domestic earnings is expected to more than offset this.
Previous-period resultsConsolidated, actual results for the same period of the previous year (second quarter of the fiscal year ended February 2026): sales ¥8,031 million, operating profit ¥110 million, ordinary profit ¥90 million, interim net income attributable to owners of the parent ¥49 million, and interim earnings per share ¥23.46. Consolidated, actual results for the previous fiscal year (fiscal year ended February 2026): sales ¥16,643 million, operating profit ¥180 million, ordinary profit ¥151 million, net income attributable to owners of the parent ¥335 million, and earnings per share ¥162.00. Non-consolidated, actual results for the previous fiscal year (fiscal year ended February 2026): sales ¥11,789 million, ordinary profit ¥279 million, net income ¥476 million, and earnings per share ¥230.39.
Consolidated / non-consolidatedConsolidated/non-consolidated
| Item | Details |
|---|---|
| Net Sales | Subject Consolidated · second quarter (interim period) / Value 8,918, Subject Consolidated - full year / Value 18,361, Subject Non-consolidated · second quarter (interim period) / Value 6,333, Subject Non-consolidated - full year / Value 12,714 → Subject Consolidated · second quarter (interim period) / Value 9,155, Subject Consolidated - full year / Value 18,328, Subject Non-consolidated · second quarter (interim period) / Value 6,129, Subject Non-consolidated - full year / Value 11,782（Subject Consolidated · second quarter (interim period) / Value 2.7, Subject Consolidated - full year / Value -0.2, Subject Non-consolidated · second quarter (interim period) / Value -3.2, Subject Non-consolidated - full year / Value -7.3） |
| Operating profit | Subject Consolidated · second quarter (interim period) / Value 92, Subject Consolidated - full year / Value 394 → Subject Consolidated · second quarter (interim period) / Value 50, Subject Consolidated - full year / Value 261（Subject Consolidated · second quarter (interim period) / Value -45.7, Subject Consolidated - full year / Value -33.6） |
| Ordinary income | Subject Consolidated · second quarter (interim period) / Value 33, Subject Consolidated - full year / Value 275, Subject Non-consolidated · second quarter (interim period) / Value 109, Subject Non-consolidated - full year / Value 263 → Subject Consolidated · second quarter (interim period) / Value -14, Subject Consolidated - full year / Value 116, Subject Non-consolidated · second quarter (interim period) / Value 16, Subject Non-consolidated - full year / Value 1（Subject Consolidated · second quarter (interim period) / Value Not disclosed, Subject Consolidated - full year / Value -57.9, Subject Non-consolidated · second quarter (interim period) / Value -84.7, Subject Non-consolidated - full year / Value -99.5） |
| Profit attributable to owners of the parent | Subject Consolidated · second quarter (interim period) / Value 11, Subject Consolidated - full year / Value 187 → Subject Consolidated · second quarter (interim period) / Value -21, Subject Consolidated - full year / Value 100（Subject Consolidated · second quarter (interim period) / Value Not disclosed, Subject Consolidated - full year / Value -46.8） |
| Net income per share | Subject Consolidated · second quarter (interim period) / Value 5.74, Subject Consolidated - full year / Value 90.78, Subject Non-consolidated · second quarter (interim period) / Value 41.22, Subject Non-consolidated - full year / Value 98.14 → Subject Consolidated · second quarter (interim period) / Value -10.56, Subject Consolidated - full year / Value 49.23, Subject Non-consolidated · second quarter (interim period) / Value 5.61, Subject Non-consolidated - full year / Value 5.02 |
| Fiscal Period Covered | Fiscal year ending February 2027 |
| Period Covered | Second quarter (interim period) and full year |
| Publication date of previous forecast | 13 April 2026 |
| Previous-period results | Consolidated, actual results for the same period of the previous year (second quarter of the fiscal year ended February 2026): sales ¥8,031 million, operating profit ¥110 million, ordinary profit ¥90 million, interim net income attributable to owners of the parent ¥49 million, and interim earnings per share ¥23.46. Consolidated, actual results for the previous fiscal year (fiscal year ended February 2026): sales ¥16,643 million, operating profit ¥180 million, ordinary profit ¥151 million, net income attributable to owners of the parent ¥335 million, and earnings per share ¥162.00. Non-consolidated, actual results for the previous fiscal year (fiscal year ended February 2026): sales ¥11,789 million, ordinary profit ¥279 million, net income ¥476 million, and earnings per share ¥230.39. |
| Reason for the revision | Orders from domestic cosmetics manufacturers fell below expectations amid heightened tensions in the Middle East, some large orders from overseas cosmetics manufacturers were postponed, costs increased due to higher crude oil prices and inflation, particularly for petroleum-derived products, and the passing of higher costs through to order prices was delayed. Sales and earnings at the French consolidated subsidiary are expected to exceed forecasts, supported by the recovery in orders for pharmaceuticals and cosmetics and the weaker yen, but the decline in domestic earnings is expected to more than offset this. |
| Consolidated / non-consolidated | Consolidated/non-consolidated |
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Individual results were weighed down by sluggish orders from domestic cosmetics manufacturers amid heightened tensions in the Middle East, the postponement of large overseas orders, higher costs caused by inflation, particularly for petroleum-derived products, and delays in passing higher costs through to prices. Although order recovery at the French consolidated subsidiary and the weaker yen boosted sales, the decline in domestic earnings more than offset these factors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.